

# COMPANY FACT SHEET

**MAGNUS MEDICAL.** A privately held medical device company currently developing a novel, rapid-acting brain stimulation technology designed to treat adults suffering from neuropsychiatric disorders. Its first application will be treatment of major depressive disorder (MDD) in adults who have not responded to existing treatments.

The company's breakthrough innovations combine advanced imaging technologies with individualized targeting and novel stimulation patterns, to yield a new approach to personalized neurostimulation for people with treatment-resistant depression (TRD). This new approach is designed to be delivered on an accelerated timeline and is precisely tailored to each person's brain connectivity.

**TECHNOLOGY AND CLINICAL RESULTS.** The Magnus System, based on SAINT technology, uses structural and functional MRI information to inform a proprietary algorithm that identifies the optimal anatomic target for focused neurostimulation in people with MDD. SAINT was developed at Stanford and licensed to Magnus Medical in October 2021 for commercialization.

For the first time, advanced tools for processing MRI-based images of the brain are used to steer a specialized, high-dose pattern of magnetic pulses to induce neurons to fire. This stimulation modifies activity in brain networks related to depression, changing the brain's circuitry to more effectively treat MDD. With this precise, personalized approach, Magnus Medical's proprietary technology for dosing and targeting may offer a new, rapid-acting treatment for intractable depression.

---

**Results from clinical trials in treatment-resistant depression show that SAINT was safe and well tolerated in the investigational setting.**

- In a pilot trial evaluating SAINT, 90% of 21 people entered remission—an elimination of depression symptoms based on accepted clinical criteria. The restoration of healthy neural activity for many people was life-changing, and within five days, symptoms, including thoughts of suicide, improved dramatically.
- In a double-blinded randomized controlled trial (RCT) evaluating SAINT, 14 people received active treatment and another 15 people received sham (placebo) treatment. The results show that 79% of people in the active treatment arm entered remission, compared to people in the sham treatment arm, where only 13% entered remission.

*The Magnus System, currently an investigational device, is expected to require 501(k) clearance from the U.S. FDA and is not yet commercially available.*

**magnusmedical**

## LEADERSHIP TEAM

Brett Wingeier, PhD, CEO  
Brandon Bentzley, MD, PhD, CSO  
Scott Ashworth, CCO

---

## HEADQUARTERS

Magnus Medical, Inc.  
1350 Old Bayshore  
Highway, Suite 600  
Burlingame, CA 94010

## EMPLOYEES

Under 20

## FINANCING

\$25M in Series A financing  
co-led by JAZZ Venture  
Partners and Red Tree  
Venture Capital.

## MEDIA RESOURCES

Brett Wingeier, Ph.D.,  
co-founder, CEO

Brandon Bentzley, M.D.,  
Ph.D., Co-founder, CSO

Scott Ashworth, CCO

## MEDIA CONTACT

Amy Cook  
[amy@magnusmed.com](mailto:amy@magnusmed.com)  
+1 925.200.2125